The therapeutic efficacy of targeting deregulated Pol I activity in cancer is currently being investigated using a selective small molecule inhibitor of Pol I transcription, CX-5461[14,174], that is in phase 1 clinical trials (Peter MacCallum Cancer Centre, Melbourne, Australia) as a mechanism to selectively and non genotoxically activate the p53 pathway in cancer cells. This evidence concerns the gene TP53 and cancer.